NRP1 and breast carcinoma: In another work, by examining EGFR trajectories in seven breast epithelial cell lines, we developed a physical phenotyping assay termed Transmembrane Receptor Dynamics (TReD) that can assess the metastatic potential of breast cancer cells (Liu et al., 2019a).